Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer Patients
Open Access
- 28 March 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (4) , 542
Abstract
Background/Objectives: Epigenetic modifications, particularly DNA methylation, contribute to tumor progression and therapy resistance. Guadecitabine, a hypomethylating agent (HMA), has shown promising clinical activity when combined with carboplatin in preclinical models. We evaluated the combination of guadecitabine with carboplatin as a second-line treatment for extensive-stage small-cell lung cancer (SCLC; NCT03913455), one of the deadliest malignancies. Here, we report methylome changes in peripheral blood mononuclear cells (PBMCs) collected at baseline and during treatment from patients on the trial. Methods: PMBC DNA was analyzed using Infinium HumanMethylationEPIC v1.0 bead chips. Data were processed, and differentially methylated positions (DMPs) were identified and analyzed for pathway enrichment using bioinformatic approaches, and immune deconvolution analyses were conducted to investigate the impact on immune cell composition. Results: Direct comparison of PBMCs between cycle 2 day 5 (C2D5; post-treatment) vs. cycle 1 day 1 (C1D1; pre-treatment) revealed a greater number of hypomethylated DMPs (380 DMPs in C2D5 vs. C1D1 PBMCs; p < 0.05, |β| > 20%). Moreover, when first compared with normal PBMCs from cancer-free controls, the number of hypomethylated DMPs was even greater in C2D5 than in C1D1 (1771 vs. 237 DMPs, respectively; p < 0.05, |β| > 20%). Long interspersed nucleotide elements-1 (LINE-1) were significantly hypomethylated in PBMCs after HMA treatment (C2D5 vs. C1D1). Pathway analysis of hypomethylated DMPs revealed significant alterations in key signaling pathways, including NF-κB, Rho GTPase, and pulmonary fibrosis in C1D1 vs. C2D5. Normal PBMCs to C1D1 PBMCs revealed changes in IL-3 signaling, Fcγ receptor-mediated phagocytosis, and molecular mechanisms of cancer. Deconvolution analysis revealed a greater percentage of monocytes in C1D1 vs. normal PBMCs; after HMA treatment, percentages of monocytes and B cells decreased, while the eosinophil percentage increased in C1D1 vs. C2D5. Conclusions: HMA treatment has a global impact on PBMC methylomes in cancer patients. DNA methylation changes were associated with biological pathways related to PBMC function, and shifts in distinct immune cell populations were observed.Keywords
Funding Information
- Van Andel Research Institute—Stand Up To Cancer Epigenetics Dream Team
- National Cancer Institute (P30CA082709-25)
- Merck and Astex, Inc.
This publication has 38 references indexed in Scilit:
- Decoding the epigenetic landscape: ctDNA methylation as a game-changer in hepatocellular carcinoma managementBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025
- Epigenetic modifications: Key players in cancer heterogeneity and drug resistanceTranslational Oncology, 2023
- Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapyCell Reports, 2023
- A multiplex blood-based assay targeting DNA methylation in PBMCs enables early detection of breast cancerNature Communications, 2023
- A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung CancerClinical Lung Cancer, 2023
- Blood-based DNA methylation signatures in cancer: A systematic reviewBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2022
- Global DNA methylation profile at LINE-1 repeats and promoter methylation of genes involved in DNA damage response and repair pathways in human peripheral blood mononuclear cells in response to γ-radiationMolecular and Cellular Biochemistry, 2021
- Idiopathic pulmonary fibrosis (IPF) signaling pathways and protective roles of melatoninLife Sciences, 2018
- What's New in SCLC? A ReviewNeoplasia, 2017
- Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturationNature Communications, 2015